A pharmaceutical composition which composition comprises an insulin sensitiser and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of the insulin sensitiser and the use of such composition in medicine.

A method for the promotion of growth and/or repair of neurons in diseases or conditions characterised by neuron degeneration, injury or impaired plasticity which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of a PPAR gamma agonist or a pharmaceutically acceptable derivative thereof.

1. A composition comprising from 2 to 12 mg 5-[[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidyl-2,4-dione of Compound (I) or a pharmaceutically acceptable form and insulin for the treatment of diabetes of type 2 and conditions associated with diabetes type 2. 2. The composition according to claim 1, comprising from 2 to 4 mg, from 4 to 8 mg or from 8 to 12 mg of Compound (I) or a pharmaceutically acceptable form. 3. The composition according to claim 1 or 2, comprising from 2 to 4 mg...

A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of Compound (I) and insulin to a mammal in nee